50503-69-0 Usage
Uses
Used in Pharmaceutical Industry:
2-[(4-chlorophenyl)amino]-6-methylquinolin-4-yl(piperidin-2-yl)methanol is used as an intermediate in the synthesis of various pharmaceutical compounds for [application reason]. Its unique structural features allow for the development of new drugs targeting specific diseases or conditions.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 2-[(4-chlorophenyl)amino]-6-methylquinolin-4-yl(piperidin-2-yl)methanol is used as a key compound for [application reason] in the design and synthesis of novel therapeutic agents. Its structural diversity and potential pharmacological activities make it a valuable tool for researchers in the development of new drugs.
Used in Drug Discovery:
2-[(4-chlorophenyl)amino]-6-methylquinolin-4-yl(piperidin-2-yl)methanol is utilized in drug discovery as a lead compound for [application reason]. Its structural characteristics can be exploited to identify new therapeutic targets and develop innovative treatments for various medical conditions.
Note: The specific application reasons (e.g., targeting a particular disease, enhancing drug efficacy, etc.) would depend on the actual pharmacological properties and potential therapeutic applications of the compound, which are not provided in the given materials.
Check Digit Verification of cas no
The CAS Registry Mumber 50503-69-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,0,5,0 and 3 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 50503-69:
(7*5)+(6*0)+(5*5)+(4*0)+(3*3)+(2*6)+(1*9)=90
90 % 10 = 0
So 50503-69-0 is a valid CAS Registry Number.
50503-69-0Relevant academic research and scientific papers
COMPOUNDS AND USE FOR TREATING CANCER
-
, (2016/08/17)
The present invention relates to certain 2,4-disubstituted quinoline derivatives, to their therapy, as well as to pharmaceutical compositions comprising said compounds. More specifically the invention relates to certain 2,4-disubstituted quinoline derivatives or pharmaceutical compositions comprising said compounds for the treatment of cancers characterized by overactive Ras and/or Rac or signalling pathway.
